A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
← catalyst calendarNCT06400472 · readout ≤ 193 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
495estimated
Sites
23
Countries
Australia, France, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-20 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Neoplasms
- Endometrial Neoplasms
- Uterine Cervical Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
- Pancreatic Neoplasm
- Colorectal Neoplasms
Interventions
- Drug: LY4170156 — also filed as sofetabart mipitecan
- Drug: bevacizumab
- Drug: carboplatin
- Drug: Itraconazole
- Drug: pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156
measured 1 Cycle (21 days)
Phase 1a: To determine the RP2D or optimal dose of LY4170156 with bevacizumab
measured 1 Cycle (21 days)
Phase 1a: To determine the RP2D or optimal dose of LY4170156 with carboplatin
measured 1 Cycle (21 days)
Phase 1a: To determine the RP2D or optimal dose of LY4170156 with pembrolizumab
measured 1 Cycle (21 days)
Phase 1b: To assess the antitumor activity of LY4170156 Monotherapy: Overall response rate (ORR)
measured Up to Approximately 48 Months or 4 Years
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Up to Approximately 48 Months or 4 Years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed